Show simple item record

dc.contributor.authorHansen, Ellen-Sofie
dc.contributor.authorHindberg, Kristian
dc.contributor.authorLatysheva, Nadezhda
dc.contributor.authorAukrust, Pål
dc.contributor.authorUeland, Thor
dc.contributor.authorHansen, John-Bjarne
dc.contributor.authorBrækkan, Sigrid Kufaas
dc.contributor.authorMorelli, Vania Maris
dc.date.accessioned2020-11-05T09:36:55Z
dc.date.available2020-11-05T09:36:55Z
dc.date.issued2020-10-15
dc.description.abstractGrowth differentiation factor 15 (GDF-15), a marker of inflammation and oxidative stress, has emerged as a biomarker for arterial cardiovascular disease. However, the association between GDF-15 and venous thromboembolism (VTE) remains uncertain. We therefore investigated the association between plasma GDF-15 levels and future risk of incident VTE and explored the potential of a causal association using Mendelian randomization (MR). We conducted a population-based nested case-control study comprising 416 VTE patients and 848 age- and sex-matched controls derived from the Tromsø Study. Logistic regression was used to calculate odds ratios (ORs) for VTE across GDF-15 quartiles. For the MR, we used data from the International Network on Venous Thrombosis (INVENT) consortium to examine whether single nucleotide polymorphisms (SNPs) associated with GDF-15 levels with genome-wide significance were related to VTE. We found that the ORs for VTE increased across GDF-15 quartiles (P<sub>trend</sub> = .002). Participants with GDF-15 values in the highest quartile (≥358 pg/mL) had an OR for VTE of 2.05 (95% confidence interval, 1.37-3.08) compared with those with GDF-15 in the lowest quartile (<200 pg/mL) in the age- and sex-adjusted model. ORs remained essentially the same after further adjustment for body mass index, smoking, hormone therapy, physical activity, and C-reactive protein. Similar results were obtained for provoked/unprovoked events, deep vein thrombosis, and pulmonary embolism. GDF-15 levels, as predicted by the SNPs, were not associated with VTE in MR. Our results indicate that high GDF-15 levels are associated with increased risk of VTE, but MR suggests that this association is not causal.en_US
dc.descriptionThis research was originally published in Blood. Hansen, E.-S., Hindberg, K., Latysheva, N., Aukrust, P., Ueland, T., Hansen, J.-B. ... Morelli, V.M. (2020). Plasma levels of growth differentiation factor 15 are associated with future risk of venous thromboembolism. <i>Blood, 136</i>(16), 1863-1870. © the American Society of Hematology.en_US
dc.identifier.citationHansen, Hindberg, Latysheva, Aukrust, Ueland, Hansen, Brækkan, Morelli. Plasma levels of growth differentiation factor 15 are associated with future risk of venous thromboembolism. Blood. 2020;136(16):1863-1870en_US
dc.identifier.cristinIDFRIDAID 1843909
dc.identifier.doi10.1182/blood.2019004572
dc.identifier.issn0006-4971
dc.identifier.issn1528-0020
dc.identifier.urihttps://hdl.handle.net/10037/19764
dc.language.isoengen_US
dc.publisherAmerican Society of Hematologyen_US
dc.relation.journalBlood
dc.rights.accessRightsopenAccessen_US
dc.rights.holder© the American Society of Hematologyen_US
dc.subjectVDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710en_US
dc.subjectVDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710en_US
dc.titlePlasma levels of growth differentiation factor 15 are associated with future risk of venous thromboembolismen_US
dc.type.versionacceptedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record